BioCentury | Aug 1, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Hyaluronan synthase 2 (HAS2); hyaluronidase 2 (HYAL2) In vitro and rodent studies suggest extremely high molecular mass hyaluronan (HMM-HA) could...
BioCentury | Apr 15, 2013
Clinical News

Hyal regulatory update

...still in clinical development, to patients for whom alternative drugs were ineffective or not tolerated. Hyal Pharmaceutical Corp....
BioCentury | Apr 15, 2013
Company News

Hyal, McMaster University, Natural Sciences and Engineering Research Council of Canada deal

...may pursue licensing of the technology after preclinical studies are completed. (HYALF patent, see B7.) Hyal Pharmaceutical Corp....
BioCentury | Apr 15, 2013
Clinical News

Hyal regulatory update

...different forms of the acid and the acid combined with drugs to treat reperfusion injury. Hyal Pharmaceutical Corp....
BioCentury | Apr 15, 2013
Clinical News

Hyal regulatory update

...sun damage to skin). The patent protects the company's Solarase topical treatment for actinic keratosis Hyal Pharmaceutical Corp....
BioCentury | Jun 2, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Hyalurono-glucosaminidase 1 (HYAL1) Cell culture and mouse studies suggest inhibiting the proangiogenic HYAL1 with sulfated hyaluronic acid could help treat prostate cancer....
BioCentury | Apr 16, 2001
Company News

Fred Hutchinson Cancer Research Center other research news

Researchers published in the Proceedings of the National Academy of Sciences that the human tumor suppressor candidate HYAL2 gene product, which mediates cell entry of Jaagsietke sheep retrovirus (JRSV), is responsible for the oncogenic activity...
BioCentury | Oct 23, 2000
Clinical News

Solaraze regulatory update

...obtained the product, which also is approved in Canada and Europe, through its acquisition of Hyal Pharmaceutical Corp....
...Ontario) (see BioCentury, Nov. 1, 1999). SkyePharma plc (LSE:SKP; SKYE), London, U.K. Product: Solaraze (Solarase, HYAL-CT1101...
BioCentury | Oct 2, 2000
Clinical News

Solarase regulatory update

...obtained the product, which also is approved in Canada and Europe, through its acquisition of Hyal Pharmaceutical Corp....
...Ontario) (see BioCentury, Nov. 1, 1999). SkyePharma plc (LSE:SKP; SKYE), London, U.K. Product: Solarase ( HYAL-CT1101...
BioCentury | Mar 14, 2000
Company News

Bioglan licenses Solarase

...Solarase is approved in five EU states. SKP obtained Solarase from its 1999 acquisition of Hyal...
Items per page:
1 - 10 of 95
BioCentury | Aug 1, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Hyaluronan synthase 2 (HAS2); hyaluronidase 2 (HYAL2) In vitro and rodent studies suggest extremely high molecular mass hyaluronan (HMM-HA) could...
BioCentury | Apr 15, 2013
Clinical News

Hyal regulatory update

...still in clinical development, to patients for whom alternative drugs were ineffective or not tolerated. Hyal Pharmaceutical Corp....
BioCentury | Apr 15, 2013
Company News

Hyal, McMaster University, Natural Sciences and Engineering Research Council of Canada deal

...may pursue licensing of the technology after preclinical studies are completed. (HYALF patent, see B7.) Hyal Pharmaceutical Corp....
BioCentury | Apr 15, 2013
Clinical News

Hyal regulatory update

...different forms of the acid and the acid combined with drugs to treat reperfusion injury. Hyal Pharmaceutical Corp....
BioCentury | Apr 15, 2013
Clinical News

Hyal regulatory update

...sun damage to skin). The patent protects the company's Solarase topical treatment for actinic keratosis Hyal Pharmaceutical Corp....
BioCentury | Jun 2, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Hyalurono-glucosaminidase 1 (HYAL1) Cell culture and mouse studies suggest inhibiting the proangiogenic HYAL1 with sulfated hyaluronic acid could help treat prostate cancer....
BioCentury | Apr 16, 2001
Company News

Fred Hutchinson Cancer Research Center other research news

Researchers published in the Proceedings of the National Academy of Sciences that the human tumor suppressor candidate HYAL2 gene product, which mediates cell entry of Jaagsietke sheep retrovirus (JRSV), is responsible for the oncogenic activity...
BioCentury | Oct 23, 2000
Clinical News

Solaraze regulatory update

...obtained the product, which also is approved in Canada and Europe, through its acquisition of Hyal Pharmaceutical Corp....
...Ontario) (see BioCentury, Nov. 1, 1999). SkyePharma plc (LSE:SKP; SKYE), London, U.K. Product: Solaraze (Solarase, HYAL-CT1101...
BioCentury | Oct 2, 2000
Clinical News

Solarase regulatory update

...obtained the product, which also is approved in Canada and Europe, through its acquisition of Hyal Pharmaceutical Corp....
...Ontario) (see BioCentury, Nov. 1, 1999). SkyePharma plc (LSE:SKP; SKYE), London, U.K. Product: Solarase ( HYAL-CT1101...
BioCentury | Mar 14, 2000
Company News

Bioglan licenses Solarase

...Solarase is approved in five EU states. SKP obtained Solarase from its 1999 acquisition of Hyal...
Items per page:
1 - 10 of 95